首页>
外国专利>
HMPV BCG IMMUNOGENIC FORMULATION CONTAINING RECOMBINANT LIVE BCG THAT EXPRESS ANTIGENS OF METAPNEUMOVIRUS HMPV IN A SUSPENSION PREPARED FROM A LYOPHILISATE WITHOUT REQUIRING AN ADJUVANT SUITABLE FOR PHARMACEUTICAL USE
HMPV BCG IMMUNOGENIC FORMULATION CONTAINING RECOMBINANT LIVE BCG THAT EXPRESS ANTIGENS OF METAPNEUMOVIRUS HMPV IN A SUSPENSION PREPARED FROM A LYOPHILISATE WITHOUT REQUIRING AN ADJUVANT SUITABLE FOR PHARMACEUTICAL USE
The present invention relates to human metanomaviruses consisting of lyophilisates of 1 x 10 9 ufc / ml of recombinant BCG expressing the viral protein P of human metanomovirus (hMPV (gene group A1, A2, B1 and B2) Lt; RTI ID = 0.0 immunogenic / RTI agents. The vaccine may be used in a solution derived from all or a portion of the P gene of hMPV and not requiring adjuvants, stabilized and administered. The formulations may also contain combinations of the above-mentioned formulations. The formulation is stabilized by means of lyophilisation (storage range between 4 ° C and 8 ° C) in order to be continuously reconstituted in anhydrous anhydrous saline solution before use.
展开▼
